natgillin/translations-raw huggingface dataset:
Antibody or antigen-binding fragments thereof, according to claim 1, whereby the antibody or antigen-binding fragments thereof consists of an antigen-binding region that binds specifically to one or more regions of the extracellular domain of prolactin receptor (PRLR) from human, monkey and mouse, and whereby the amino acid sequences of the human PRLR are depicted by the amino acid sequences from position 1 to 210 of SEQ ID NO: 12 and human polymorphic variants of SEQ ID NO: 12, by the amino acid sequences from position 1 to 210 of the monkey PRLR according to SEQ ID NO: 11 and of the mouse PRLR according to SEQ ID NO: 13. 
Protutijelo ili njegovi fragmenti koji vežu antigen prema zahtjevu 1, naznačeno time da protutijelo ili njegovi fragmenti koji vežu antigen sadrže regiju koja veže antigen koja se specifično veže na jednu ili više regija izvanstanične domene prolaktin receptora (PRLR) iz čovjeka, majmuna i miša, te pri čemu su sekvence amino kiseline za ljudski PRLR prikazane sa sekvencom amino kiseline od položaja 1 do 210 iz SEQ ID NO: 12 i ljudske polimorfne varijante iz SEQ ID NO: 12, sa sekvencom amino kiseline od položaja 1 do 210 majmunskog PRLR u skladu sa SEQ ID NO: 11 i mišjeg PRLR u skladu sa SEQ ID NO: 13.
. photodermatoses caused by exogenous photosensitizers and especially those caused by contact photosensitizers (for example furocoumarins, halogenated salicylanilides and derivatives, and local sulfamides and derivatives) or those caused by systemic photosensitizers (for example psoralenes, tetracyclines, sulfamides, phenothiazines, nalidixic acid and tricyclic antidepressants); 
• fotodermatoza uzrokovanih egzogenim fotosenzibilizatorima, a osobito onih uzrokovanih kontaktnim fotosenzibilizatorima (primjerice furokumarinima, halogeniranim salicilanilidima i njihovim derivatima, te lokalni sulfamidima i njihovim derivatima) ili onih uzrokovanih sistemnim fotosenzibilizatorima (primjerice psoralenima, tetraciklinima, sulfamidima, fenotiazinima, nalidiksičnom kiselinom i tricikličkim antidepresivima);
The method as defined in any one of claims 12 to 15, wherein the step of deriving includes the sub-step of, when the second positioning signal transmitted from the indoor transmitter, acquiring the position data from a signal obtained through the demodulation, and the sub-step of, when a plurality of the first positioning signals are received without receiving the second positioning signal, calculating the position information based on the plurality of received spread spectrum signals. 
Metoda prema zahtjevu 8 ili 9, u kojoj korak izvođenja uključuje, kada se drugi pozicijski signal prenosi sa unutrašnjeg odašiljača, podkorak primanja podataka o poziciji posredstvom signala dobivenog demodulacijom, i, kada je primljeno više prvih pozicijskih signala bez prijema drugih pozicijskih signala, podkorak izračunavanja informacije o poziciji na osnovu više primljenih signala raširenog spektra.
The resin (4-(Chloro(diphenyl)methyl)benzoyl aminomethyl polystyrene resin) is washed 3 times with methanol and dried and could be reused. 
Smola (4-(kloro(difenil)metil) benzoil aminometil polistiren smola) se ispere tri puta metanolom i suši te se može ponovno koristiti.
A compound of the formula (I) wherein 
Spoj formule (1) gdje
The biomaterial as claimed in claim 1 or 2, wherein the weight ratio is 10:90 to 50:50 with a volume-enhancing effect. 
Biomaterijali kako su prijavljeni u patentnom zahtjevu 1, naznačeni time da maseni omjer jest 10:90 do 50:50, a da imaju učinak povećanja volumena.
An apparatus as claimed in claim 1, comprising a channel for lengthwise sliding of the wood pieces to load the conveyor system, wherein the channel is shaped to guide the wood pieces and prevent them from leaving the lengthwise orientation. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time što ima kanal (4) za uzdužno klizanje komada drva radi punjenja transportnog sustava, gdje je kanal (4) takvog oblika da vodi komade drva i sprječava da izgube uzdužnu orijentaciju.
Figure 3 depicts the reaction pathway for the synthesis of 42-O-(D-fructosylcarbonyl)rapamycin. 
Slika 3 prikazuje reakcijski put sinteze 42-O-(D-fruktozilkarbonil)rapamicina.
The pharmaceutical composition according to claim 1, wherein R1 is a hydrogen atom, R2 is a fluorine atom, and R3 is a hydrogen atom. 
Farmaceutski pripravak u skladu sa zahtjevom 1, naznačen time, da je R1 atom vodika i R2 je atom fluora.
The antigen-binding fragment of embodiment 7, wherein said fragment is selected from the group consisting of a Fab fragment, an F(ab')2 fragment, an Fv fragment, and a single-chain Fv fragment. 
Antigen-vezujući fragment prema zahtjevu 8, naznačen time da je navedeni fragment odabran iz grupe koja se sastoji od Fab fragmenta, F(ab*), fragmenta, Fv fragmenta, i jednolančanog Fv fragmenta.
Moreover, biological sources of proteins usually contain complex mixtures of materials. 
Štoviše, biološki izvori proteina uobičajeno sadrže složene mješavine materijala.
Additives having no direct influence on the potency of the active ingredient are also applicable; examples of such additives are buffer solutions, preservatives and additives which assist absorption. 
Aditivi koji nemaju izravan utjecaj na jačinu djelovanja aktivne tvari mogu se također primijeniti; primjeri takvih aditiva su otopine koje se koriste kao puferi, konzervansi i aditivi koji potpomažu apsorpciju.
evaporating the suspension medium in an air flow. 
(b) isparavanje suspenzijskog medija u struji zraka.
The set of polypeptides according to any one of claims 1 to 17, wherein said fragment F1 comprises a VL domain of an anti-CD3, anti-His or anti-DIG antibody and said fragment F2 comprises a VH domain of the same antibody, or wherein said fragment F1 comprises a VH domain of an anti-CD3 anti-His or anti-DIG antibody and said fragment F2 comprises a VL domain of the same antibody. 
Skup polipeptida u skladu s bilo kojim od patentnih zahtjeva 1 do 15, naznačen time što navedeni fragment F1 sadrži VL domenu protutijela protiv CD3, protiv His ili protiv DIG, a navedeni fragment F2 sadrži VH domenu istog protutijela, ili gdje navedeni fragment F1 sadrži VH domenu protutijela protiv CD3 protiv His ili protiv DIG, a navedeni fragment F2 sadrži VL domenu istog protutijela.
The tubes were sealed and subjected to microwave heating at 160° C. for 15 minutes. 
Cijevi su potom zatvorene i podvrgnute mikrovalnom grijanju na 160 stupnjeva C tijekom 15 minuta.
said entry transfer device fulfilling a buffer function enabling said plurality of loads to be put on hold before they are loaded onto the entry elevator, said method comprising the following acts: transferring loads via the entry sequencer, from said at least one entry interface conveyor to the K levels of the entry transfer device in forming, in the entry transfer device, groups of N loads distributed on the K levels with N being smaller than or equal to a capacity of the entry elevator in number of loads; 
– transport (71) robe, preko ulaznog sekvencera, od navedene najmanje jedne ulazne tekuće vrpce do ulaznog transportnog uređaja, tvoreći u ulaznom transportnom uređaju, skupine od N komada robe, koji se raspodjeljuje po K višetovarnih razina, gdje je N manji od ili jednak kapacitetu ulaznog dizala u broju robe, te uz, za svaku višetovarnu razinu ulaznog transportnog uređaja, sekvenciranje robe, koju navodi sustav za navođenje, u skladu s ograničavanjem spremanja N komada robe u najmanje jedan višerazinski skladišni kompleks prilikom ponavljanja navedenog ciklusa dizanja i spuštanja;
A method of treating a disease or medical condition in a patient in need thereof, wherein the disease or medical condition is selected from the group consisting of: metabolic syndrome, diabetes, obesity, and liver steatosis, comprising administering to the patient the pharmaceutical composition of claim 15 in an amount effective to treat the disease or medical condition. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 9 ili 10, naznačen time što je namijenjen upotrebi u liječenju bolesti ili medicinskog stanja koje se bira iz skupine koju čine: metabolički sindrom, dijabetes, pretilost, masna jetra i neurodegenerativna bolest.
An actuation handle assembly as defined in claim 1, wherein the covering element has an opening that is centrally aligned with the rotary axis (D) of the handle. 
Kontrolna ručica sukladno zahtjevu 9, naznačena time što pokrovni element (90) ima otvor (95) središnje poravnat s rotacijskom osi (D) ručice (20).
A dose counter according to claim 1, wherein the actuator shaft (220) is resiliently biased towards a starting position, the actuator shaft (220) being displaceable against the resilient bias for actuating the dose counter. 
Brojač doza u skladu s bilo kojim od patentnih zahtjeva 1 ili 5, pri čemu je pokretačka osovina (20) elastično odmaknuta prema početnoj poziciji, pokretačka osovina (20) se može odmaknuti naspram elastičnog pomaka za pokretanje brojača doza.
a heavy chain variable domain comprising a CDR1 region that comprises amino acids 31-35 of SEQ ID NO: 5, a CDR2 region that comprises amino acids 50-66 of SEQ ID NO: 5, and a CDR3 region that comprises amino acids 99-106 of SEQ ID NO: 5; and a light chain variable domain comprising a CDR1 region that comprises amino acids 24-38 of SEQ ID NO: 6, a CDR2 region that comprises amino acids 54-60 of SEQ ID NO: 6, and a CDR3 region that comprises amino acids 93-101 of SEQ ID NO: 6; or 
varijabilnu domenu teškog lanca koja sadrži CDR1 regiju koja sadrži aminokiseline 31-35 iz SEQ ID NO:5, CDR2 regiju koja sadrži aminokiseline 50-66 iz SEQ ID NO:5 i CDR3 regiju koja sadrži aminokiseline 99-106 iz SEQ ID NO:5; i varijabilnu domenu lakog lanca koja sadrži CDR1 regiju koja sadrži aminokiseline 24-38 iz SEQ ID NO: 6, CDR2 regiju koja sadrži aminokiseline 54-60 iz SEQ ID NO: 6 i CDR3 regiju koja sadrži aminokiseline 93-101 iz SEQ ID NO: 6; ili
represents a hydrogen atom; and R4 represents a phenyl group which is optionally substituted, a naphthyl group which is optionally substituted, or a thienyl group which is optionally substituted. 
R* predstavlja atom vodika; a R* predstavlja skupinu fenila koja je po izboru supstituirana, skupinu naftila koja je po izboru supstituirana, ili skupinu tienila koja je po izboru supstituirana,
The tablet according to claim 1, wherein the tablet has an acid neutralizing capacity of about 13 mEq to about 18 mEq. 
Tableta prema bilo kojem od gore navedenih zahtjeva, naznačena time da tableta ima kiseli neutralizacijski kapacitet od oko 13 mEq do oko 18 mEq.
The method of claim 13, wherein generating the five membered ring comprises iodination of a carbon adjacent the amine substituent of compound (III) followed by alkylation using 1,3-dihalopropene prior to generating the five membered ring. 
Postupak prema patentnom zahtjevu 13, gdje stvaranje peto-članog prstena sadrži jodiranje ugljika pored amin supstituenta spoja (III), nakon čega slijedi alkilacija primjenom 1,3-dihalopropena prije stvaranja peto-članog prstena.
The telomerase inhibitor for the use of claim 23, wherein the effective amount of a telomerase inhibitor is 7.5 mg/kg to 9.4 mg/kg. 
Inhibitor telomeraze za uporabu u skladu s patentnim zahtjevom 22, naznačen time što efikasna količina inhibitora telomeraze je 7.5 mg/kg do 9.4 mg/kg.
Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. 
Prikladna veziva uključuju škrob, želatinu, prirodne šećere kao što su glukoza ili beta-laktoza, kukuruzni zaslađivači, prirodne i sintetičke gume kao što su akacija, tragakant ili natrij alginat, karboksimetilceluloza, polietilen glikol, vosak i slično.
The compound of claim 1, wherein R7 is selected from the group consisting of H, methoxy, ethoxy, and an optionally substituted morpholinyl ring. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što se skupinu R; bira iz skupine koju čine H, metil, te trifluormetil.
Thermal after-treatment of the elastic, conductive yarn, which can, for example, be combined with a rewinding process or even takes place at the same time as the subsequent textile finishing of the finished fabric, causes the fusible fibres to adopt a plastic state and, after cooling, bond the core filament and sheath fibres, which improves the antislip properties of the hybrid yarn without noticeably reducing the electrical conductivity. 
Naknadna toplinska obrada elastične, vodljive pređe, koja može, na primjer, biti kombinirana s postupkom ponovnog omatanja ili se čak može događati u isto vrijeme kao i dorada dovršenog tekstilnog plošnog proizvoda koja slijedi nakon toga, uzrokuje da topljiva vlakna dobiju plastično stanje i nakon hlađenja povežu središnje vlakno i vlakna omotača, što poboljšava takva svojstva koja sprečavaju razdvajanje hibridne pređe, a da se pri tome primjetno ne smanji električna vodljivost.
lateral displacement of the tip perpendicular to an axis collinear with a straight shaft portion and perpendicular to an axis of a bend of the tip; twist angle along the axis collinear with a straight shaft portion of the tip; 
- < bočno premještanje vrha okomito na os koja je u istom pravcu s odsječkom ravne osovine i okomito na os od savijenog dijela vrha;
a hatch for receiving wood pieces one-by-one from the conveyor system; and 
mehanizam za punjenje (4), namijenjen dodavanju drva uzdužno na transportni sustav (5, 7);
a total amount of protein of at least 7% (w/w), 
ukupnu količinu proteina od najmanje 7 % (tež./tež.),
interruption of alcohol filling of volumetric chamber (3) by means of solenoid valves (2, 2'), 
zaustavljanja punjenja volumetrijske komore (3) alkoholom elektromagnetskim ventilima (2, 2’),
said pin (20) is interposed between said first and second plunger elements (32, 42), the latter (32, 42) being reciprocally opposite with respect to said pin (20); 
Spojnica za zatvaranje vrata prema zahtjevu 1, gdje su prvi i drugi klipni elementi (32, 42) uzajamno nasuprotni u odnosu na klin (20).
Preferred ring sizes of rings of the ring system include 5 to 6 ring atoms. 
Poželjne veličine prstena u prstenastom sustavu uključuju 5 do 6 atoma u prstenu.
The use of claim 1, wherein said pediatric acute lymphoblastic leukemia (ALL) is refractory to chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT). 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 9 ili 10, naznačen time što se postupak provodi nakon alogenog presađivanja krvotvornih matičnih stanica (HSCT).
An immunogenic composition for infants comprising a multivalent Streptococcus pneumoniae vaccine comprising capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22F saccharide conjugate, wherein the capsular saccharides present in the immunogenic composition are conjugated to a carrier protein independently selected from the group consisting of Tetanus Toxoid (TT), Diphtheria Toxoid (DT), CRM197, fragment C of TT, PhtD, PhtDE fusions, detoxified pneumolysin and protein D wherein the composition further comprises conjugates of S.pneumoniae capsular saccharides 1, 4, 5, 6B, 7F, 9V, 14, 18C and 23F and wherein the immunogenic composition comprises at least one S.pneumoniae capsular saccharide conjugated to PhtD via a linker. 
HR P20161681 T1 PATENTNI ZAHTJEVI 1. Imunogeni pripravak protiv bakterije Streptococcus pneumoniae, koji sadrži 10 ili više saharida kapsule iz različitih serotipova bakterije S. pneumoniae, konjugiranih s proteinskim nosačem, te što sadrži 3 ili više različitih proteinskih nosača, naznačen time što pripravak sadrži: saharid iz kapsule serotipa 19F, konjugiran s difterijskim toksoidom (DT); saharid iz kapsule serotipa 18C, konjugiran s tetanusnim toksoidom (TT); saharidi iz kapsule serotipova 1, 4, 5, 6B, 7F, 9V, 14 1 23F, konjugirani s proteinom D iz bakterije Haemophilus influenzae.
The at least two constituents of the additive are present in the following proportions: Ternesite or ternesite clinker in a range from 10 to 99% by weight, preferably 20 to 95% by weight and even more preferably 40 to 90% by weight, and a source of rapidly available aluminum in a range from 1 to 90% by weight, preferably 5 to 80% by weight and even more preferably 10 to 60% by weight. 
Vezivo sukladno zahtjevu 3, naznačeno time što sadrži klinker kalcijevog sulfoaluminata u količimi opsega od 10 do 90 % mase, poželjno 20 do 70 % mase i ternesit klinker u količini opsega od 10 do 90 % mase, poželjno 30 do 80 % mase, pri čemu sve komponente veziva iznose do 100 %.
The composition according to claim 1 comprising about 2 mg to about 50 mg of buprenorphine. 
Ni, Pripravak sukladno patentnom zahtjevu 1 sadrži 2 mg do 50 mg buprenorfina.
removing the G groups to form a compound of formula (VIIa) or (VIIb): or an acid addition salt thereof. 
uklanjanje G grupa da bi se formirao spoj formule (VIIa) ili (VIIb): [image] ili njegova kisela adicijska sol.
Enantiomerically pure compounds of formula (I) are available by way of chirally selective synthesis or by way of chiral separation. 
Enantiomerno čiste spojeve formule (Ia), (Ib) 1 (Ic) može se dobiti kiralno selektivnom sintezom ili kiralnim razdvajanjem.
• polyamidoamine hardeners which are obtained by condensation of mono- and polycarboxylic acids with polyamines, especially by condensation of dimer fatty acids with polyalkylenepolyamines; 
• poliamidoaminski učvršćivači koji se dobivaju kondenzacijom mono- i polikarboksilnih kiselina s poliaminima, naročito kondenzacijom dimernih masnih kiselina s polialkilenpoliaminima;
A compound according to claim 2 wherein substructure IV is chosen from the group consisting of and 
Spoj u skladu s patentnim zahtjevom 2, gdje podstrukturu IV se bira iz skupine koju čine [image] [image] i [image]
wherein step d) is performed after step c) or simultaneously with step c); and rolling a thread in the form of a trapezoidal thread having a flank angle of less than 10° at least partially on the pipe portion. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se na dijelu cijevi (76) obrađenom postupkom nareže navoj, u obliku trapezoidnog navoja s bočnim kutom manjim od 15°, osobito 10°.
• a nozzle (16) configured to apply a coating material onto an inner wall of a said tube, 
* mlaznicu (16) koja je konfigurirana za nanošenje premaza na unutarnju stijenku navedene cijevi, *
In another aspect, the crenolanib or a pharmaceutically acceptable salt thereof is provided at least one of sequentially or concomitantly, with another pharmaceutical agent in a newly diagnosed proliferative disorder patient, to maintain remission of an existing patient, or a relapsed/refractory proliferative disease patient. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 1, pri čemu je terapeutski djelotvorna količina crenolaniba ili njegove farmaceutski prihvatljive soli osigurana barem jednom slijedno ili istodobno s drugim farmaceutskim agensom subjektu s novodijagnosticiranom akutnom mijeloičnom leukemijom (AML), za održavanje remisije kod subjekta ili subjektu s relapsiranom ili akutnom mijeloičnom leukemijom (AML).
If it is correctly positioned, it has been found that a sampler of this type makes it possible to obtain good results with respect to obtaining endometrial tissue. 
Ako se naprava za uzimanje uzorka točno postavi, nađeno je da naprava ove vrste omogućava dobivanje dobrih rezultata koji se odnose na dobivanje tkiva sluznice maternice.
6-8 BV of the main peak was collected, starting from the increase in absorbance. 
6-8 BV glavnoga pika bilo je sakupljeno, započinjući od trenutka kada se apsorbancija počela povećavati.
The combination for use as claimed in claim 4, wherein about 20-700 µg, or 20-350 µg of the compound (i) are applied to the eye of the subject from 1 to 2 times daily. 
Kombinacija za uporabu u skladu s patentnim zahtjevom 4, pri čemu se otprilike 20-700 µg, ili 20-350 µg tvari (i) primjenjuje u oko subjekta od 1 do 2 puta na dan.
Pharmaceutical, cosmetic and/or dietary composition according to claim 1, comprising a mixture characterized in that it comprises between three and ten fatty acids. 
Smjesa za primjenu prema patentnom zahtjevu 1, naznačena time da sadrži deset masnih kiselina.
Where it occurs in formulae (I), (Ia), (Ib) or other formulae elsewhere in this specification, R8 preferably is the side chain residue of an a-amino acid selected from the group consisting of arginine, aspartic acid, citrulline, glutamic acid, glutamine, glycine, histidine, lysine, phenylalanine, serine, threonine, tryptophan, tyrosine, and valine. 
NHC(=0)R'"; R* je ostatak bočnog lanca o-amino kiseline odabrane od grupe koja se sastoji od alanin, arginin, asparagin, asparaginska kiselina, y-karboksiglutaminska kiselina, citrulin, cistein, glutaminska kiselina, glutamin, glicin, histidin, izoleucin, leucin, lizin, metionin, norleucin, norvalin, ornitin, fenilalanin, serin, treonin, triptofan, tirozin, i valin;
A compound consisting of an antisense oligomer that is 16 contiguous nucleotides in length, wherein the sequence of the antisense oligomer is 100% complementary to the sequence of SEQ ID NO: 31, wherein the antisense oligomer is a gapmer comprising at least one LNA unit, and wherein the antisense oligomer targets mRNA encoding PCSK9. 
Antisens oligonukleotidni konjugat naznačen time što sadrži antisens oligomer (A) od između 16 - 22 nukleotida u dužini, koji sadrži neprekidnu sekvencu od 16 nukleotida koji su komplementarni odgovarajućoj dužini SEQ ID NO 31, i pri čemu je navedeni antisens oligomer LNA gapmer, i
about 1.5 % to about 1.7 % (w/w) testosterone; 
1.62% (w/w) testosterona
The nucleic acid probe according to claim 19, wherein said nucleic acid probe consists in a nucleic acid sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 87. 
Uporaba prema zahtjevu 15, naznačena time što se navedena sonda nukleinske kiseline sastoji od sekvence nukleinske kiseline odabrane iz skupine koju čine SEQ ID NO: 6 do SEQ ID NO: 87.
The whole was then heated up to 94°C and it was then additioned with the acid catalyst (formic acid); the pH was equal to 4.5. The mixture was then condensed at 95°C until reaching a viscosity of 100 cP (measured at 20°C). 
Zagrijemo do 94"C te dodamo kiseli katalizator (mravlju kiselinu), pH je 4,5. Kondenziramo kod 95*C do viskoznosti 0,1 Pa.s. (mjereno kod 20%C).
Tetramethylsilane (TMS) was used as internal reference standard. 
Kao standardna unutarnja referenca upotrijebljen je tetrametilsilan (TMS).
treating the boronic ester compound of formula (XVI) with a reagent of formula M1-N(Si(R6)3)2, where M1 is an alkali metal and each R6 independently is selected from the group consisting of alkyl, aralkyl, and aryl, where the aryl or aryl portion of the aralkyl is optionally substituted, to form a compound of formula (XVII): 
tretman spoja estera organoborne kiseline formule (XVI) sa reagensom formule M1-N(G)2, gdje je M1 alkalni metal i svako G pojedinačno ili zajedno je zaštitna grupa amino grupe, da bi se formirao spoj formule (XVII): [image]
A process according to claim 4 wherein said dimethylsulfoxonium methylide is prepared in situ from the corresponding sulfoxonium halide by reaction with a base in the presence of an organic solvent. 
Postupak prema zahtjevu 4 gdje se dimetilsulfoksonij metilid priprema in situ iz odgovarajućeg sulfoksonij halida reakcijom s bazom u prisutnosti organskog otapala.
The edge portion 61 of the outer part 62 holds the inner part 60, and the sidewall of the inner part 60 comprises reinforcement ribs 63. 
Rubni predio 61 vanjskog dijela 62 ima unutarnji dio 60, a bočna stijenka unutarnjeg dijela 60 ima rebra za pojačanje